 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the firm, MarketBeat.com...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts

This price move could indicate a change in the trend, and may be a buy signal for investors...

Celldex Therapeutics (CLDX, $42.18) price moved above its 50-day Moving Average on March 20, 2024

Celldex Therapeutics, Inc. (NASDAQ:CLDX  Get Free Report) was the target of a large decline in short interest in the month of February. As of February 29th, there was short interest totalling...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

GSA Capital Partners LLP lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX  Free Report) by 192.0% in the 3rd quarter, according to its most recent Form 13F filing with the...

GSA Capital Partners LLP Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global...

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Celldex Therapeutics, Inc. (CLDX), where a total of 9,083 contracts have traded so far...

Notable Wednesday Option Activity: CLDX, GOOG, PSFE

This is a signal that CLDX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Celldex Therapeutics (CLDX, $50.01) RSI Indicator left the overbought zone on March 05, 2024

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an...

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ( Celldex or the Company ) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public...

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Volume (M)	110,613.00
52-Wk High	$53.18
52-Wk Low	$22.11

CLDX Celldex Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals